Thirteen patients in a cohort of 340 cancer patients who received genetically modified immune cells developed 16 secondary cancers in the months or years following treatment, a rate comparable to patients who receive standard-of-care therapies, including chemotherapy and hematopoietic stem cell transplant. Researchers reviewed biopsy results for 11 of the secondary tumors and found no transferred genetic material from the therapy.
Study shows long-term safety of genetically modified immune effector cells miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.